Hikma Pharmaceutical | HIK - Selling And Administration Expenses


Hikma Pharmaceutical reported $288M in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
argenx SE USD 355M 74.62M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Autolus Therapeutics Ltd USD 39.95M 4.16M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Fresenius EUR 819M 143M Dec/2025
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
GRIFOLS EUR 281M 5.7M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Merck EUR 1.52B 80M Mar/2026
Orion EUR 91.9M 18.8M Mar/2026
Recordati EUR 192.76M 5.52M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
UCB EUR 1.47B 193M Dec/2025